Top 10 Companies in the (S)-1-(3-Bromophenyl)-ethylamine (CAS 139305-96-7) Market (2026): Market Leaders Powering Global Pharmaceutical Development

MARKET INSIGHTS

Global (S)-1-(3-Bromophenyl)-ethylamine (CAS 139305-96-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-1-(3-Bromophenyl)-ethylamine (CAS 139305-96-7) is a chiral building block and specialty fine chemical widely utilized in asymmetric synthesis and pharmaceutical intermediate development. Characterized by its enantiopure (S)-configuration, this brominated aromatic amine serves as a critical precursor in the synthesis of active pharmaceutical ingredients (APIs), agrochemicals, and advanced materials. Its high stereochemical purity makes it particularly valuable in drug discovery workflows where enantiomeric selectivity directly influences therapeutic efficacy and safety profiles.

The market is gaining steady momentum, driven primarily by the expanding pharmaceutical R&D pipeline globally and the growing preference for enantioselective synthesis over racemic approaches. Furthermore, increasing demand from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) for high-purity chiral intermediates continues to support market expansion. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, Combi‑Blocks, and AK Scientific, among others, offering this compound across varying purity grades to meet diverse research and commercial‑scale requirements.

(S)-1-(3-Bromophenyl)-ethylamine (CAS 139305-96-7) Market – View in Detailed Research Report

MARKET DRIVERS

Rising Demand from Pharmaceutical Synthesis and Chiral Chemistry Applications

(S)-1-(3-Bromophenyl)-ethylamine (CAS 139305-96-7) is a chiral building block with well‑established utility in asymmetric synthesis, and its demand has grown alongside the broader pharmaceutical industry’s shift toward enantiomerically pure active pharmaceutical ingredients (APIs). Regulatory agencies including the FDA and EMA have increasingly required that drug developers characterize and, where appropriate, develop single‑enantiomer formulations rather than racemic mixtures. This regulatory direction has made high‑purity chiral amines such as (S)-1-(3‑Bromophenyl)-ethylamine indispensable in the early stages of drug discovery and development. The compound’s secondary amine functionality and aryl bromide moiety allow it to participate in a wide range of coupling reactions, including Suzuki, Buchwald‑Hartwig, and Negishi cross‑coupling reactions, making it a versatile precursor in medicinal chemistry workflows.

Expansion of Contract Research and Contract Manufacturing Organizations (CROs and CMOs)

The global expansion of CROs and CMOs has directly supported demand for specialized chiral intermediates. As pharmaceutical companies increasingly outsource early‑stage synthesis and scale‑up activities, contract organizations require reliable access to enantiopure reagents such as (S)-1-(3‑Bromophenyl)-ethylamine to meet client specifications. This compound, with its defined stereochemistry confirmed by optical rotation and chiral HPLC analysis, fits squarely into the inventory requirements of organizations supplying custom synthesis services. Furthermore, the growth of small‑molecule drug discovery programs targeting CNS disorders, oncology, and cardiovascular conditions has kept demand for structurally complex chiral amines at a steady level, as these therapeutic areas frequently involve nitrogen‑containing scaffolds where stereochemical control is critical to pharmacological activity and selectivity.

➤ The aryl bromide functionality in (S)-1-(3-Bromophenyl)-ethylamine serves as a highly versatile handle for palladium‑catalyzed cross‑coupling reactions, enabling medicinal chemists to rapidly diversify molecular scaffolds during lead optimization campaigns – a capability that has made this building block particularly valuable in high‑throughput synthesis environments.

Academic and industrial research institutions involved in developing new chiral catalysts and asymmetric methodologies also contribute to steady consumption of this compound. Because (S)-1‑(3‑Bromophenyl)-ethylamine is commercially available from several specialty chemical suppliers at high enantiomeric excess (typically ≥98% ee), researchers can reliably benchmark synthetic outcomes, which has reinforced its position as a reference substrate in peer‑reviewed asymmetric synthesis studies. This dual utility – both as a direct synthetic building block and as a research tool – broadens its market relevance beyond any single end‑use application.

MARKET CHALLENGES

Stringent Handling, Storage, and Regulatory Compliance Requirements

(S)-1‑(3‑Bromophenyl)-ethylamine presents handling challenges typical of reactive amine compounds. It requires storage under inert atmosphere conditions at controlled low temperatures, generally between 2°C and 8°C, to preserve enantiomeric integrity and prevent oxidative degradation. This adds logistical complexity and cost to its supply chain, particularly for international shipments that must maintain cold‑chain conditions. Additionally, the compound’s amine functionality means it is susceptible to carbamation upon exposure to atmospheric carbon dioxide, which can compromise purity if handling protocols are not strictly followed. For smaller research laboratories with limited infrastructure, maintaining compliant storage and handling conditions can represent a meaningful operational burden.

Other Challenges

Limited Number of Qualified Suppliers
The market for (S)-1‑(3‑Bromophenyl)-ethylamine is served by a relatively concentrated group of specialty chemical producers and fine chemical distributors, including companies such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals, Combi‑Blocks, and Enamine, among others. While these suppliers generally maintain consistent quality, the limited supplier base creates potential vulnerabilities in terms of pricing flexibility and supply continuity. Customers requiring large quantities for scale‑up or commercial manufacturing may face lead time constraints or minimum order requirements that are not well‑suited to agile drug development timelines.

Price Sensitivity in Research Budgets
Chiral amines produced in high enantiomeric excess typically carry a price premium compared to their racemic counterparts due to the cost of asymmetric synthesis or chiral resolution processes. For academic institutions and early‑stage biotech companies operating under constrained research budgets, the cost of enantiopure reagents like (S)-1‑(3‑Bromophenyl)-ethylamine can limit consumption volumes. This price sensitivity is particularly pronounced in markets outside North America and Western Europe, where purchasing power disparities and import duties may further elevate the effective cost of specialty chiral intermediates.

MARKET RESTRAINTS

Niche Application Scope and Dependence on Pharmaceutical R&D Spending Cycles

The market for (S)-1‑(3‑Bromophenyl)-ethylamine is inherently niche, as its primary utility is concentrated within pharmaceutical synthesis, asymmetric catalysis research, and specialty chemical manufacturing. Unlike commodity chemicals that serve broad industrial end markets, demand for this compound is closely tied to the volume and direction of pharmaceutical R&D pipelines and academic research funding. Periods of reduced drug development activity – whether driven by macroeconomic pressures, changes in venture funding for biotech, or shifts in therapeutic area priorities – can translate directly into reduced procurement of specialized building blocks. This cyclical dependency limits the ability of suppliers to achieve the stable, predictable demand curves that typically support capacity investment and pricing stability.

Competition from Alternative Chiral Amine Building Blocks and In‑House Synthesis

Medicinal chemists have access to a broad portfolio of chiral amine building blocks, and the selection of (S)-1‑(3‑Bromophenyl)-ethylamine for a given project is contingent on the specific structural requirements of the target molecule. Alternative bromophenyl‑substituted amines, as well as other halogenated arylethylamine derivatives with varying substitution patterns, may be preferred depending on the electronic and steric demands of the synthesis. Furthermore, organizations with strong synthetic capabilities may elect to prepare this compound in‑house via asymmetric reductive amination or chiral resolution of the racemic precursor, bypassing commercial procurement entirely. This in‑house synthesis option acts as a structural restraint on commercial market volumes, particularly for larger pharmaceutical companies with well‑resourced process chemistry groups.

MARKET OPPORTUNITIES

Growing Adoption of Chiral Building Blocks in Targeted Small‑Molecule Drug Discovery

The continued growth of precision medicine and targeted therapeutics represents a meaningful opportunity for the (S)-1‑(3‑Bromophenyl)-ethylamine market. As drug developers pursue increasingly selective small‑molecule candidates – particularly kinase inhibitors, GPCR modulators, and protease‑targeting agents – the demand for structurally defined chiral intermediates that enable stereocontrolled synthesis has expanded. The aryl bromide group in this compound is particularly well‑suited to late‑stage diversification strategies, where a common chiral amine scaffold is functionalized via cross‑coupling to generate compound libraries for structure‑activity relationship (SAR) studies. This approach, widely adopted in contemporary medicinal chemistry, positions (S)-1‑(3‑Bromophenyl)-ethylamine as a productive entry point into enantioselective library synthesis programs.

Expansion of Specialty Chemical Supply Networks in Asia‑Pacific

The Asia‑Pacific region, particularly China and India, has seen significant investment in fine chemical and specialty pharmaceutical ingredient manufacturing infrastructure over the past decade. Several Chinese chemical producers have developed capabilities in chiral amine synthesis and have begun offering enantiopure building blocks – including meta‑substituted arylethylamines – at competitive price points with improving quality standards. This geographic expansion of the supply base presents an opportunity to reduce the cost of (S)-1‑(3‑Bromophenyl)-ethylamine for end users, potentially broadening its adoption among cost‑sensitive research organizations. Simultaneously, the growing domestic pharmaceutical R&D activity in China, India, South Korea, and Japan is generating new demand for chiral intermediates that was previously concentrated primarily in North America and Europe, creating additional consumption channels that could support overall market growth for this compound category.

Top 10 Companies in the (S)-1-(3‑Bromophenyl)-ethylamine Market

10️⃣ 1. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical‑grade chiral amines, analytical reagents, and custom synthesis services.

Sigma‑Aldrich is a global leader in fine chemicals and specialty reagents. Their extensive portfolio of chiral building blocks, including (S)-1‑(3‑Bromophenyl)-ethylamine, is supported by rigorous quality control, GMP compliance, and comprehensive analytical data.